Hussein Ezzeldin

Hussein Ezzeldin

Senior Staff Fellow at U.S. FDA

Dr. Ezzeldin earned his PhD in 2012 from the University of Maryland, College Park in multiscale modeling of soft matter. He joined the Office of Biostatistics and Pharmacovigilance (OBPV) in 2013. During more than nine years with OBPV, he has worked on multiple modeling and risk assessment, policy and research projects. Currently he is the lead for the digital health technology review team (DHTRT), supporting the use of DHTs in regulatory submissions. In addition, Dr. Ezzeldin co-leads the Biologics Effectiveness and Safety Innovative Methods Initiative, which aims to develop new and innovative methods for a semi-automated adverse events reporting system for CBER-Regulated Biological Products. Also, Dr. Ezzeldin has a passion for advancing the science of patient input, and he is leading the natural history study for metachromatic leukodystrophy, HOME. Dr. Ezzeldin led the development of the open-sourced Survey of Health And Patient Experience platform, a versatile data collection platform for patient-centered studies.

Sessions
Improving and Expediting Biologics Adverse Event Surveillance Using FHIR®
Thursday, March 14 11:30 AM - 12:30 PM Eastern Time (US & Canada)